Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: A retrospective analysis of 58 patients

J Am Acad Dermatol. 2021 Jan;84(1):206-207. doi: 10.1016/j.jaad.2020.04.118. Epub 2020 Apr 26.

Authors

Ellen E Anshelevich¹, John S Barbieri¹, Carrie L Kovarik²

Affiliations

¹ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: carrie.kovarik@pennmedicine.upenn.edu.

PMID: 32348821
DOI: 10.1016/j.jaad.2020.04.118

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Antiviral Agents / administration & dosage
Antiviral Agents / therapeutic use*
Child
Cidofovir / administration & dosage
Cidofovir / therapeutic use*
Female
Humans
Immunocompetence
Immunocompromised Host
Injections, Intralesional
Male
Middle Aged
Retrospective Studies
Warts / drug therapy*
Young Adult

Substances

Antiviral Agents
Cidofovir